Enanta Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Enanta Pharmaceuticals, Inc.‘s stocks are currently a part of 93 hedge funds’ portfolios, which represents 36.93% of the total amount of its stocks outstanding. This makes up a total of 7.68M shares of Enanta Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -59.82% or -11.44M shares fewer. As for the holding position changes, 30.11% (28) of current hedge fund investors increased the number of shares held, 44.09% (41) of current holders sold a part of the shares held, and 5.38% (5) closed the holdings completely. 6 hedge funds are new holders of Enanta Pharmaceuticals, Inc. stock in Q1 2023, it is 6.45% of total holders.
Hedge funds holding Enanta Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 188 |
|---|---|
| Q3 2018 | 193 |
| Q4 2018 | 180 |
| Q1 2019 | 192 |
| Q2 2019 | 191 |
| Q3 2019 | 173 |
| Q4 2019 | 168 |
| Q1 2020 | 152 |
| Q2 2020 | 176 |
| Q3 2020 | 167 |
| Q4 2020 | 149 |
| Q1 2021 | 146 |
| Q2 2021 | 148 |
| Q3 2021 | 144 |
| Q4 2021 | 177 |
| Q1 2022 | 162 |
| Q2 2022 | 148 |
| Q3 2022 | 155 |
| Q4 2022 | 143 |
| Q1 2023 | 93 |
Hedge funds changes in Enanta Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 29 | 74 | 57 | 18 | 10 |
|---|---|---|---|---|---|
| Q3 2018 | 33 | 77 | 63 | 27 | -7 |
| Q4 2018 | 21 | 78 | 54 | 36 | -9 |
| Q1 2019 | 27 | 74 | 59 | 14 | 18 |
| Q2 2019 | 28 | 77 | 55 | 26 | 5 |
| Q3 2019 | 13 | 81 | 54 | 31 | -6 |
| Q4 2019 | 23 | 62 | 63 | 22 | -2 |
| Q1 2020 | 18 | 61 | 48 | 33 | -8 |
| Q2 2020 | 39 | 63 | 52 | 15 | 7 |
| Q3 2020 | 15 | 76 | 55 | 24 | -3 |
| Q4 2020 | 9 | 57 | 60 | 27 | -4 |
| Q1 2021 | 13 | 54 | 57 | 14 | 8 |
| Q2 2021 | 18 | 46 | 60 | 16 | 8 |
| Q3 2021 | 10 | 41 | 71 | 13 | 9 |
| Q4 2021 | 44 | 64 | 49 | 10 | 10 |
| Q1 2022 | 17 | 63 | 63 | 32 | -13 |
| Q2 2022 | 12 | 54 | 55 | 21 | 6 |
| Q3 2022 | 20 | 62 | 48 | 16 | 9 |
| Q4 2022 | 10 | 55 | 48 | 21 | 9 |
| Q1 2023 | 6 | 28 | 41 | 5 | 13 |
Hedge funds changes in Enanta Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 11,469,000 | 8,924,000 |
|---|---|---|
| Q3 2018 | 7,514,000 | 6,183,000 |
| Q4 2018 | 4,555,000 | 4,426,000 |
| Q1 2019 | 5,138,000 | 7,514,000 |
| Q2 2019 | 4,514,000 | 12,176,000 |
| Q3 2019 | 5,216,000 | 7,204,000 |
| Q4 2019 | 7,969,000 | 5,029,000 |
| Q1 2020 | 2,324,000 | 3,152,000 |
| Q2 2020 | 269,000 | 1,774,000 |
| Q3 2020 | 4,000 | 2,147,000 |
| Q4 2020 | 58,000 | 3,570,000 |
| Q1 2021 | 2,081,000 | 5,390,000 |
| Q2 2021 | 1,601,000 | 3,287,000 |
| Q3 2021 | 2,919,000 | 53,000 |
| Q4 2021 | 2,864,000 | 23,466,000 |
| Q1 2022 | 4,492,000 | 1,759,000 |
| Q2 2022 | 7,162,000 | 619,000 |
| Q3 2022 | 11,733,000 | 1,260,000 |
| Q4 2022 | 10,554,612 | 175,820 |
| Q1 2023 | 16,000 | 36,000 |